NEW YORK, June 11 - Galapagos Genomics has signed on to provide Procter & Gamble Pharmaceuticals with protein drug targets related to osteoporosis, the Mechelen, Belgium, company said today.
Under the agreement, Galapagos will provide Proctor & Gamble with protein targets that impact bone formation. Proctor & Gamble will validate the targets and may initiate development of osteoporosis drug candidates based on these targets.
Galapagos is to receive option fees, milestone payments, and royalties on sales of any products developed from these targets, the company said, but did not disclose further financial terms of the deal.
Galapagos has discovered these targets using PhenoSelect, its gene expression platform which uses arrayed adenoviruses containing human genes to identify and validate targets.
This agreement expands on a a previous deal in which Proctor & Gamble agreed to use PhenoSelect to discover targets internally.